Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Profound Medical (PROF) Research & Development (2024 - 2025)

Profound Medical has reported Research & Development over the past 2 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Research & Development at $4.3 million for Q4 2025, down 8.11% from a year ago — trailing twelve months through Dec 2025 was $20.6 million (up 21.4% YoY), and the annual figure for FY2025 was $20.6 million, up 21.4%.
  • Research & Development for Q4 2025 was $4.3 million at Profound Medical, down from $5.4 million in the prior quarter.
  • Over the last five years, Research & Development for PROF hit a ceiling of $6.1 million in Q2 2025 and a floor of $3.9 million in Q1 2024.